andrographolide and Disease-Models--Animal

andrographolide has been researched along with Disease-Models--Animal* in 3 studies

Other Studies

3 other study(ies) available for andrographolide and Disease-Models--Animal

ArticleYear
Synthesis and evaluation of andrographolide derivatives as potent anti-osteoporosis agents in vitro and in vivo.
    European journal of medicinal chemistry, 2021, Mar-05, Volume: 213

    In this work, we found that 14-deoxy-11,12-didehydroandrographolide (2), a derivative of andrographolide (AP, 1), had greatly reduced cytotoxicity compared with AP and exhibited moderate anti-osteoclastogenesis activity. Thirty compounds were synthesized by introducing anti-osteoporosis chemotypes at C-19 of 2. Six of them exhibited stronger inhibition of osteoclastogenesis than AP. Of note, compound 12g displayed the most potent activity with IC

    Topics: Animals; Bone Resorption; Cell Differentiation; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Female; Mice; Mice, Inbred C57BL; Molecular Structure; Osteoclasts; Osteogenesis; Osteoporosis; RAW 264.7 Cells; Structure-Activity Relationship

2021
Synthesis of new andrographolide derivatives and evaluation of their antidyslipidemic, LDL-oxidation and antioxidant activity.
    European journal of medicinal chemistry, 2013, Volume: 69

    Andrographis paniculata, native to Taiwan, Mainland China and India, is a medicinal herb, which possesses various biological activities including anti-atherosclerosis. Andrographolide (1) has been identified as one of the active constituents against atherosclerosis. In continuation of our drug discovery program we synthesized few novel derivatives of 1 to improve their antidyslipidemic, LDL-oxidation and antioxidant activity. The tosylated derivative 7 has been turned out to be more potent than the parent compound and comparable activity with marketed antidyslipidemic drugs.

    Topics: Animals; Antioxidants; Disease Models, Animal; Diterpenes; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Male; Molecular Structure; Oxidation-Reduction; Rats; Rats, Inbred Strains

2013
Protective role of 14-deoxy-11,12-didehydroandrographolide, a noncytotoxic analogue of andrographolide, in allergic airway inflammation.
    Journal of natural products, 2011, Jun-24, Volume: 74, Issue:6

    Our group recently reported novel anti-inflammatory effects of andrographolide (2), a bioactive molecule isolated from Andrographis paniculata, in a mouse asthma model. However, 2 has been shown to possess cytotoxic activity. 14-Deoxy-11,12-didehydroandrographolide (1) is an analogue of 2 that can be isolated from A. paniculata. We hypothesized that 1 retains the anti-inflammatory effects for asthma but is devoid of cytotoxicity. In contrast to 2, 1 did not elicit any cytotoxic activity in A549 and BEAS-2B human lung epithelial cells and rat basophilic leukemia (RBL)-2H3 cells using a MTS assay. Compound 1 dose-dependently inhibited ovalbumin (OVA)-induced increases in total and eosinophil counts, IL-4, IL-5, and IL-13 levels in lavage fluid, and serum OVA-specific IgE level in a mouse asthma model. Compound 1 attenuated OVA-induced airway eosinophilia, mucus production, mast cell degranulation, pro-inflammatory biomarker expression in lung tissues, and airway hyper-responsiveness. This substance also blocked p65 nuclear translocation and DNA-binding activity in the OVA-challenged lung and in TNF-α-stimulated human lung epithelial cells. The present findings reveal for the first time that 1 retains the anti-inflammatory activities of 2 for asthma probably through the inhibition of NF-κB. 14-Deoxy-11,12-didehydroandrographolide (1) may be considered as a safer analogue of 2 for the potential treatment of asthma.

    Topics: Andrographis; Animals; Anti-Inflammatory Agents; Asthma; Disease Models, Animal; Diterpenes; Humans; Lung; Mice; NF-kappa B; Ovalbumin; Rats; Tumor Necrosis Factor-alpha

2011